Tuesday, April 23, 2019 3:31:45 PM
its easy when you can manipulate.
First- have a plan to do a secondary for much higher than you can do now.
Second-Do a hype PR by saying something exciting but nonspecific to get investors to rush in-
something like "significant discovery" in treatment of lung cancer- something like that to make people thing you have found a cure.
But don't tell them what it is because it's really not that exciting to get the stock price up to do the secondary.
It's so significant they have to wait a couple of days to tell you about it. Its so significant we can't tell you about it now separately, we need to lump it in with other stuff like FDA comments and other corporate developments. To make it look like we are not trying to make you buy the stock on our hype PR but we had other legitimate reasons for the PR.
Third-after the price is up-just llke you planned, announce the secondary.
First- have a plan to do a secondary for much higher than you can do now.
Second-Do a hype PR by saying something exciting but nonspecific to get investors to rush in-
something like "significant discovery" in treatment of lung cancer- something like that to make people thing you have found a cure.
But don't tell them what it is because it's really not that exciting to get the stock price up to do the secondary.
It's so significant they have to wait a couple of days to tell you about it. Its so significant we can't tell you about it now separately, we need to lump it in with other stuff like FDA comments and other corporate developments. To make it look like we are not trying to make you buy the stock on our hype PR but we had other legitimate reasons for the PR.
Third-after the price is up-just llke you planned, announce the secondary.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 12:30:15 PM
- Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 12:00:58 PM
- Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks • GlobeNewswire Inc. • 05/13/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 01:30:19 PM
- Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits • GlobeNewswire Inc. • 05/12/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:45:12 PM
- Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin • GlobeNewswire Inc. • 05/08/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 12:25:26 PM
- Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 • GlobeNewswire Inc. • 04/23/2026 12:25:00 PM
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 12:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 03:40:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/15/2026 04:15:07 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/14/2026 09:26:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/14/2026 08:56:35 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
- Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
